effect of abcb1 and abcc3 polymorphisms on osteosarcoma survival after chemotherapy a pharmacogenetic study种代号为abcb1的效果和abcc3多态性在化疗后骨肉瘤的生存药理遗传学研究.pdfVIP

Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study 1 ˜ 2 ´ ´ 3 1 1 Daniela Caronia , Ana Patino-Garcia , Antonio Perez-Martınez , Guillermo Pita , Leticia Tais Moreno , ´ 2 3 3 ´ 2 ´ 1,4 Marta Zalacain-Dıez , Blanca Molina , Isabel Colmenero , Luis Sierrasesumaga , Javier Benıtez , Anna Gonzalez-Neira1* 1 Human Genotyping Unit-CeGen, Spanish National Cancer Research Centre, Madrid, Spain, 2 Department of Pediatrics, University of Navarra and University Clinic, ˜ Pamplona, Spain, 3 Pediatric Oncology Department, Universitary Children’s Hospital Nino Jesus, Madrid, Spain, 4 Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain Abstract Background: Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adriamycin, and methotrexate before surgical resection of the primary tumour, followed by postoperative chemotherapy including vincristine and cyclophosphamide. Unfortunately, many patients still relapse or suffer adverse events. We examined whether common germline polymorphisms in chemotherapeutic transporter and metabolic pathway genes of the drugs used in standard osteosarcoma treatment may predic